The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors

Objective To evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for desmoid tumors (DTs).Method A total 111 patients with histologically proven DTs were included treated by USgHIFU ablation. Adverse events continuously evaluated according to Common Terminology Criteria Events (CTCAE) v5.0 until 3 months after treatment. The incidence non-perfused areas within tumors, volume rate (NPVR) tumor reduction using contrast-enhanced MRI before one week procedure.Results enrolled (32 male, 79 female, mean age 29.5 ± 1.0 years) 145 (118 extra-abdominal, 16 abdominal wall, 11 intra-abdominal; median maximum diameter: 9.6 cm, range: 3–34.5 cm) underwent 188 sessions HIFU ablation, number ablations was 1.7 (range, 1–7) per patient. In majority cases (143/145 cases, 98.6%), no serious adverse observed. There significant difference in between who received a single treatment those multiple treatments. Non-perfused area observed every tumor, NPVR 84.9% 1.9–100%). 36.1 4.2% at treatment.Conclusion as noninvasive easily repeatable local treatment, is promising DTs.